RB/E2F Regulation and Dual Activity in the Melanocytic System View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2006-01-01

AUTHORS

Ruth Halaban

ABSTRACT

Retinoblastoma (RB) is a tumor suppressor that represses the expression of E2F-regulated genes required for cell cycle progression. It is inactivated in melanomas and other cancer cells by phosphorylation catalyzed by persistent cyclin-dependent kinase (CDK) activity. CDK activity is sustained in melanoma cells mostly by the elimination of the CDK inhibitor, p16INK4A, and by high levels of cyclins, whose expression is maintained by stimuli emanating from activated cell-surface receptors and/or by mutated intracellular intermediates, such as N-Ras and B-Raf. However, RB also suppresses the expression of apoptosis genes, and its presence protects normal melanocytes from cell death. Its high expression in human melanoma cells and tumors suggests a similar positive effect on the viability of the malignant cells as well. The release and suppression of E2F transcriptional activity is likely to depend on promoter-specific RB/E2F interaction. Phosphorylated RB is displaced from cell cycle genes but not from others. In addition, RB gene repression is dependent on the nature of RB/E2F interaction and the composition of RB-bound proteins possessing specific chromatin modification activities recruited to the promoter. Deciphering the differences in RB/E2F complex formation in normal and malignant melanocytes is likely to shed light on the mechanism by which RB can exert tumor suppressing and promoting activities in this cellular system. The RB/E2F pathway provides opportunities for efficient therapy at multiple levels. Novel drugs can reactivate RB potential to suppress growth cycle-promoting genes. In addition, the high E2F transcriptional activity in melanoma cells can be exploited to deliver cytotoxic molecules specifically to tumors, sparing the normal tissues. More... »

PAGES

223-245

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-1-59259-994-3_13

DOI

http://dx.doi.org/10.1007/978-1-59259-994-3_13

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1047873712


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biological Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Biochemistry and Cell Biology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Dermatology, Yale University School of Medicine, New Haven, CT", 
          "id": "http://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Dermatology, Yale University School of Medicine, New Haven, CT"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Halaban", 
        "givenName": "Ruth", 
        "id": "sg:person.053601122.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.053601122.01"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2006-01-01", 
    "datePublishedReg": "2006-01-01", 
    "description": "Retinoblastoma (RB) is a tumor suppressor that represses the expression of E2F-regulated genes required for cell cycle progression. It is inactivated in melanomas and other cancer cells by phosphorylation catalyzed by persistent cyclin-dependent kinase (CDK) activity. CDK activity is sustained in melanoma cells mostly by the elimination of the CDK inhibitor, p16INK4A, and by high levels of cyclins, whose expression is maintained by stimuli emanating from activated cell-surface receptors and/or by mutated intracellular intermediates, such as N-Ras and B-Raf. However, RB also suppresses the expression of apoptosis genes, and its presence protects normal melanocytes from cell death. Its high expression in human melanoma cells and tumors suggests a similar positive effect on the viability of the malignant cells as well. The release and suppression of E2F transcriptional activity is likely to depend on promoter-specific RB/E2F interaction. Phosphorylated RB is displaced from cell cycle genes but not from others. In addition, RB gene repression is dependent on the nature of RB/E2F interaction and the composition of RB-bound proteins possessing specific chromatin modification activities recruited to the promoter. Deciphering the differences in RB/E2F complex formation in normal and malignant melanocytes is likely to shed light on the mechanism by which RB can exert tumor suppressing and promoting activities in this cellular system. The RB/E2F pathway provides opportunities for efficient therapy at multiple levels. Novel drugs can reactivate RB potential to suppress growth cycle-promoting genes. In addition, the high E2F transcriptional activity in melanoma cells can be exploited to deliver cytotoxic molecules specifically to tumors, sparing the normal tissues.", 
    "editor": [
      {
        "familyName": "Hearing", 
        "givenName": "Vincent J.", 
        "type": "Person"
      }, 
      {
        "familyName": "Leong", 
        "givenName": "Stanley P. L.", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-1-59259-994-3_13", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-1-58829-459-3", 
        "978-1-59259-994-3"
      ], 
      "name": "From Melanocytes to Melanoma", 
      "type": "Book"
    }, 
    "keywords": [
      "E2F transcriptional activity", 
      "E2F interaction", 
      "transcriptional activity", 
      "Rb/E2F pathway", 
      "chromatin modification activities", 
      "cyclin-dependent kinase activity", 
      "E2F-regulated genes", 
      "Rb-binding protein", 
      "cell cycle genes", 
      "E2F complex formation", 
      "melanoma cells", 
      "cell cycle progression", 
      "cell surface receptors", 
      "gene repression", 
      "E2F regulation", 
      "cycle genes", 
      "E2F pathway", 
      "CDK activity", 
      "kinase activity", 
      "apoptosis genes", 
      "B-Raf", 
      "cycle progression", 
      "tumor suppressor", 
      "CDK inhibitors", 
      "N-ras", 
      "cell death", 
      "human melanoma cells", 
      "genes", 
      "normal melanocytes", 
      "modification activities", 
      "intracellular intermediates", 
      "melanocytic system", 
      "cancer cells", 
      "phosphorylated retinoblastoma", 
      "malignant melanocytes", 
      "RB potential", 
      "complex formation", 
      "high expression", 
      "expression", 
      "dual activity", 
      "cells", 
      "melanocytes", 
      "cellular systems", 
      "cytotoxic molecules", 
      "malignant cells", 
      "novel drugs", 
      "normal tissues", 
      "repression", 
      "phosphorylation", 
      "promoter", 
      "retinoblastoma", 
      "suppressor", 
      "cyclin", 
      "multiple levels", 
      "similar positive effects", 
      "protein", 
      "activity", 
      "regulation", 
      "pathway", 
      "high levels", 
      "p16INK4a", 
      "interaction", 
      "efficient therapy", 
      "inhibitors", 
      "receptors", 
      "viability", 
      "tissue", 
      "molecules", 
      "mechanism", 
      "intermediates", 
      "levels", 
      "progression", 
      "suppression", 
      "positive effect", 
      "addition", 
      "composition", 
      "tumors", 
      "formation", 
      "release", 
      "death", 
      "presence", 
      "light", 
      "stimuli", 
      "potential", 
      "melanoma", 
      "system", 
      "effect", 
      "differences", 
      "nature", 
      "drugs", 
      "elimination", 
      "opportunities", 
      "therapy"
    ], 
    "name": "RB/E2F Regulation and Dual Activity in the Melanocytic System", 
    "pagination": "223-245", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1047873712"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-1-59259-994-3_13"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-1-59259-994-3_13", 
      "https://app.dimensions.ai/details/publication/pub.1047873712"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-12-01T06:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/chapter/chapter_224.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-1-59259-994-3_13"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-1-59259-994-3_13'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-1-59259-994-3_13'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-1-59259-994-3_13'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-1-59259-994-3_13'


 

This table displays all metadata directly associated to this object as RDF triples.

165 TRIPLES      22 PREDICATES      119 URIs      110 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-1-59259-994-3_13 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 anzsrc-for:11
4 anzsrc-for:1112
5 schema:author N545981863d17414ba1cc996e6a73a88e
6 schema:datePublished 2006-01-01
7 schema:datePublishedReg 2006-01-01
8 schema:description Retinoblastoma (RB) is a tumor suppressor that represses the expression of E2F-regulated genes required for cell cycle progression. It is inactivated in melanomas and other cancer cells by phosphorylation catalyzed by persistent cyclin-dependent kinase (CDK) activity. CDK activity is sustained in melanoma cells mostly by the elimination of the CDK inhibitor, p16INK4A, and by high levels of cyclins, whose expression is maintained by stimuli emanating from activated cell-surface receptors and/or by mutated intracellular intermediates, such as N-Ras and B-Raf. However, RB also suppresses the expression of apoptosis genes, and its presence protects normal melanocytes from cell death. Its high expression in human melanoma cells and tumors suggests a similar positive effect on the viability of the malignant cells as well. The release and suppression of E2F transcriptional activity is likely to depend on promoter-specific RB/E2F interaction. Phosphorylated RB is displaced from cell cycle genes but not from others. In addition, RB gene repression is dependent on the nature of RB/E2F interaction and the composition of RB-bound proteins possessing specific chromatin modification activities recruited to the promoter. Deciphering the differences in RB/E2F complex formation in normal and malignant melanocytes is likely to shed light on the mechanism by which RB can exert tumor suppressing and promoting activities in this cellular system. The RB/E2F pathway provides opportunities for efficient therapy at multiple levels. Novel drugs can reactivate RB potential to suppress growth cycle-promoting genes. In addition, the high E2F transcriptional activity in melanoma cells can be exploited to deliver cytotoxic molecules specifically to tumors, sparing the normal tissues.
9 schema:editor Ne20910baf81d42fc86975764ff8c77c4
10 schema:genre chapter
11 schema:isAccessibleForFree false
12 schema:isPartOf N158760cce3c54c0cb449189c82dc417e
13 schema:keywords B-Raf
14 CDK activity
15 CDK inhibitors
16 E2F complex formation
17 E2F interaction
18 E2F pathway
19 E2F regulation
20 E2F transcriptional activity
21 E2F-regulated genes
22 N-ras
23 RB potential
24 Rb-binding protein
25 Rb/E2F pathway
26 activity
27 addition
28 apoptosis genes
29 cancer cells
30 cell cycle genes
31 cell cycle progression
32 cell death
33 cell surface receptors
34 cells
35 cellular systems
36 chromatin modification activities
37 complex formation
38 composition
39 cycle genes
40 cycle progression
41 cyclin
42 cyclin-dependent kinase activity
43 cytotoxic molecules
44 death
45 differences
46 drugs
47 dual activity
48 effect
49 efficient therapy
50 elimination
51 expression
52 formation
53 gene repression
54 genes
55 high expression
56 high levels
57 human melanoma cells
58 inhibitors
59 interaction
60 intermediates
61 intracellular intermediates
62 kinase activity
63 levels
64 light
65 malignant cells
66 malignant melanocytes
67 mechanism
68 melanocytes
69 melanocytic system
70 melanoma
71 melanoma cells
72 modification activities
73 molecules
74 multiple levels
75 nature
76 normal melanocytes
77 normal tissues
78 novel drugs
79 opportunities
80 p16INK4a
81 pathway
82 phosphorylated retinoblastoma
83 phosphorylation
84 positive effect
85 potential
86 presence
87 progression
88 promoter
89 protein
90 receptors
91 regulation
92 release
93 repression
94 retinoblastoma
95 similar positive effects
96 stimuli
97 suppression
98 suppressor
99 system
100 therapy
101 tissue
102 transcriptional activity
103 tumor suppressor
104 tumors
105 viability
106 schema:name RB/E2F Regulation and Dual Activity in the Melanocytic System
107 schema:pagination 223-245
108 schema:productId N0950a359260c4cd4864fff785fd52f20
109 N8077dae4728247ec85fd3cfdde9b7019
110 schema:publisher N84d168f394bb4043b6d1f9e820a5cb4b
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047873712
112 https://doi.org/10.1007/978-1-59259-994-3_13
113 schema:sdDatePublished 2022-12-01T06:49
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher N10bedb67460f47f2b0c2b2eddaa4c65e
116 schema:url https://doi.org/10.1007/978-1-59259-994-3_13
117 sgo:license sg:explorer/license/
118 sgo:sdDataset chapters
119 rdf:type schema:Chapter
120 N0950a359260c4cd4864fff785fd52f20 schema:name dimensions_id
121 schema:value pub.1047873712
122 rdf:type schema:PropertyValue
123 N10bedb67460f47f2b0c2b2eddaa4c65e schema:name Springer Nature - SN SciGraph project
124 rdf:type schema:Organization
125 N158760cce3c54c0cb449189c82dc417e schema:isbn 978-1-58829-459-3
126 978-1-59259-994-3
127 schema:name From Melanocytes to Melanoma
128 rdf:type schema:Book
129 N545981863d17414ba1cc996e6a73a88e rdf:first sg:person.053601122.01
130 rdf:rest rdf:nil
131 N8077dae4728247ec85fd3cfdde9b7019 schema:name doi
132 schema:value 10.1007/978-1-59259-994-3_13
133 rdf:type schema:PropertyValue
134 N84d168f394bb4043b6d1f9e820a5cb4b schema:name Springer Nature
135 rdf:type schema:Organisation
136 N8731142851914e659463476e5962bfeb schema:familyName Hearing
137 schema:givenName Vincent J.
138 rdf:type schema:Person
139 Na316042750b345089b45f7ce25e719eb schema:familyName Leong
140 schema:givenName Stanley P. L.
141 rdf:type schema:Person
142 Ncc511f18aab14031b434663c3193b2de rdf:first Na316042750b345089b45f7ce25e719eb
143 rdf:rest rdf:nil
144 Ne20910baf81d42fc86975764ff8c77c4 rdf:first N8731142851914e659463476e5962bfeb
145 rdf:rest Ncc511f18aab14031b434663c3193b2de
146 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
147 schema:name Biological Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
150 schema:name Biochemistry and Cell Biology
151 rdf:type schema:DefinedTerm
152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
153 schema:name Medical and Health Sciences
154 rdf:type schema:DefinedTerm
155 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
156 schema:name Oncology and Carcinogenesis
157 rdf:type schema:DefinedTerm
158 sg:person.053601122.01 schema:affiliation grid-institutes:grid.47100.32
159 schema:familyName Halaban
160 schema:givenName Ruth
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.053601122.01
162 rdf:type schema:Person
163 grid-institutes:grid.47100.32 schema:alternateName Department of Dermatology, Yale University School of Medicine, New Haven, CT
164 schema:name Department of Dermatology, Yale University School of Medicine, New Haven, CT
165 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...